Gemigliptin, a DPP4 inhibitor, ameliorates nonalcoholic steatohepatitis through AMP-activated protein kinase-independent and ULK1-mediated autophagy

OBJECTIVE: Abnormal autophagic function and activated inflammasomes are typical features in the liver of patients with non-alcoholic steatohepatitis (NASH). Here, we explored whether gemigliptin, a dipeptidyl peptidase 4 (DPP4) inhibitor for treatment of type 2 diabetes, can induce autophagy and reg...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Youngmi, Yang, Hyekyung, Kim, Juhee, Lee, Yoonjin, Kim, Sung-Ho, Do, In-Gu, Park, Cheol-Young
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10542016/
https://www.ncbi.nlm.nih.gov/pubmed/37739179
http://dx.doi.org/10.1016/j.molmet.2023.101806

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10542016/
https://www.ncbi.nlm.nih.gov/pubmed/37739179
http://dx.doi.org/10.1016/j.molmet.2023.101806

Ejemplares similares